New malaria vaccine for pregnant women enters human testing
NCT ID NCT02658253
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a vaccine called PRIMVAC, designed to prevent malaria during pregnancy. Researchers gave three different doses to 68 healthy adults in France and Burkina Faso to check safety and immune response. The vaccine targets a protein that helps malaria parasites attach to the placenta.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PRIMVAC vaccine (a protein from the malaria parasite) with either Alhydrogel or GLA-SE adjuvant
What this could lead to
If successful, this could lead to a vaccine that protects pregnant women from placental malaria, preventing severe complications for mothers and babies.
What could go wrong
This is an early Phase 1 trial with only 68 participants, focused on safety and immune response, not yet on preventing disease. The vaccine may not produce strong enough immunity or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CIC 1417
Paris, 75679, France
-
CNRFP
Ouagadougou, BP 2208, Burkina Faso